Correlation of polymorphisms to coagulation and biochemical risk factors for cardiovascular diseases.

[1]  J. Stokes.  Book Review A War of Nerves: Soldiers and Psychiatrists in the Twentieth Century By Ben Shephard. 487 pp., illustrated. Cambridge, Mass., Harvard University Press, 2001. $27.95. 0-674-00592-9 , 2001 .

[2]  M. Hirata,et al.  Seven DNA polymorphisms at the candidate genes of atherosclerosis in Brazilian women with angiographically documented coronary artery disease. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[3]  D. Girelli,et al.  Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. , 2000, The New England journal of medicine.

[4]  C. Mirkin,et al.  Scanometric DNA array detection with nanoparticle probes. , 2000, Science.

[5]  A. Catapano,et al.  Low density lipoprotein oxidation, antioxidants, and atherosclerosis , 2000, Current opinion in cardiology.

[6]  A. Reiner,et al.  Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. , 2000, Stroke.

[7]  Jin Q. Kim,et al.  Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and coagulation factor VII Arg353-->Gln polymorphism in Korean patients with coronary artery disease. , 2000, Journal of Korean medical science.

[8]  B. Damasceno,et al.  Inherited Thrombophilia as a Risk Factor for the Development of Ischemic Stroke in Young Adults , 2000, Thrombosis and Haemostasis.

[9]  K. Kawazoe,et al.  Genetic polymorphism of 5,10‐methylenetetrahydrofolate increases risk of myocardial infarction and is correlated to elevated levels of homocysteine in the Japanese general population , 2000, Coronary artery disease.

[10]  G J Tsongalis,et al.  Polymorphisms in the genes for coagulation factors II, V, and VII in patients with ischemic heart disease. , 1999, Archives of pathology & laboratory medicine.

[11]  A. Carter,et al.  Association of the platelet glycoprotein IIb HPA-3 polymorphism with survival after acute ischemic stroke. , 1999, Stroke.

[12]  N. Bornstein,et al.  The A677V methylenetetrahydrofolate reductase gene polymorphism and carotid atherosclerosis. , 1999, Stroke.

[13]  J. Gorący,et al.  [C677T gene polymorphism of methylenetetrahydrofolate reductase (MTHFR) in patients with myocardial infarction]. , 1999, Polskie Archiwum Medycyny Wewnetrznej.

[14]  M. Margaglione,et al.  Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Margaglione,et al.  Prothrombotic genetic risk factors in young survivors of myocardial infarction. , 1999, Blood.

[16]  I. Bata,et al.  Relation of genetic polymorphisms of apolipoprotein E, angiotensin converting enzyme, apolipoprotein B-100, and glycoprotein IIIa and early-onset coronary heart disease. , 1999, Clinical biochemistry.

[17]  B. Modan,et al.  Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. , 1999, Blood.

[18]  P. Ridker,et al.  G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. , 1999, Circulation.

[19]  A. Kastrati,et al.  PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. , 1999, Circulation.

[20]  J. Carlquist,et al.  Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. , 1999, Journal of the American College of Cardiology.

[21]  R. Press,et al.  Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke. , 1999, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[22]  M. Laule,et al.  A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter interventions: a case-controlled study , 1999, The Lancet.

[23]  P. Ridker,et al.  Factor V Leiden is not a risk factor for myocardial infarction among young women. , 1999, Blood.

[24]  D. Coakley,et al.  Genetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[25]  M. Kaste,et al.  Genetic Polymorphism of Platelet Glycoprotein IIIa in Patients with Acute Myocardial Infarction and Acute Ischaemic Stroke , 1999, Journal of cardiovascular risk.

[26]  L. Deecke,et al.  C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. , 1999, Thrombosis research.

[27]  P. Reitsma,et al.  The 20210 G → A mutation in the 3′‐untranslated region of the prothrombin gene and the risk for arterial thrombotic disease , 1999, British journal of haematology.

[28]  F. Burzotta,et al.  The 4G/5G Polymorphism of PAI-1 Promoter Gene and the Risk of Myocardial Infarction: A Meta-analysis , 1998, Thrombosis and Haemostasis.

[29]  Y. Yazaki,et al.  Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[30]  J. Stricker,et al.  Association of the Platelet Glycoprotein IIIa PIA1/A2 Gene Polymorphism to Coronary Artery Disease but not to Nonfatal Myocardial Infarction in Low Risk Patients , 1998, Thrombosis and Haemostasis.

[31]  M. Delgado-Rodríguez,et al.  Polymorphism of the Platelet Glycoprotein IIIa Gene in Patients with Coronary Stenosis , 1998, Thrombosis and Haemostasis.

[32]  P. Chiusolo,et al.  Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. , 1998, Blood.

[33]  M. Roden,et al.  Inherited platelet glycoprotein polymorphisms and a risk for coronary heart disease in young central Europeans. , 1998, Thrombosis research.

[34]  T. Arinami,et al.  Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. , 1998, Atherosclerosis.

[35]  T. Raghunathan,et al.  Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) , 1998, Stroke.

[36]  P. de Knijff,et al.  Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. , 1998, The New England journal of medicine.

[37]  D. Ardissino,et al.  The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[38]  J. Carlquist,et al.  A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. , 1997, Journal of the American College of Cardiology.

[39]  A. Carter,et al.  Association of the Platelet PlA Polymorphism of Glycoprotein IIb/IIIa and the Fibrinogen Bβ 448 Polymorphism With Myocardial Infarction and Extent of Coronary Artery Disease , 1997 .

[40]  F R Rosendaal,et al.  A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. , 1997, Blood.

[41]  H. Markus,et al.  A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. , 1997, Stroke.

[42]  T. Raghunathan,et al.  Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. , 1997, Circulation.

[43]  T. Raghunathan,et al.  Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. , 1997, Blood.

[44]  Y. Yazaki,et al.  Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. , 1997, Circulation.

[45]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[46]  P. Frosst,et al.  Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[47]  P. Ridker,et al.  PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis , 1997, The Lancet.

[48]  B. Giusti,et al.  Prevalence of Factor V Leiden Mutation in Non-European Populations , 1997, Thrombosis and Haemostasis.

[49]  W. Willett,et al.  Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. , 1996, Circulation.

[50]  A. Carter,et al.  Platelet glycoprotein IIIa PIA polymorphism in young men with myocardial infarction , 1996, The Lancet.

[51]  J. Weiss,et al.  A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. , 1996, The New England journal of medicine.

[52]  S. Devaraj,et al.  Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. , 1996, Clinical chemistry.

[53]  D. Arveiler,et al.  Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indicator of MI risk in the ECTIM study. , 1996, Atherosclerosis.

[54]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[55]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[56]  B. Winkelmann,et al.  Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease , 1995, The Lancet.

[57]  A. Evans,et al.  Myocardial infarction, Arg 506 to Gin factor V mutation, and activated protein C resistance , 1995, The Lancet.

[58]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[59]  M. Malinow,et al.  Homocyst(e)ine and coronary artery disease , 1992 .

[60]  R. Lawn,et al.  Lipoprotein(a) and atherosclerosis. , 1991, Annals of internal medicine.

[61]  Young Women. , 1875, Hall's journal of health.

[62]  P. Renshaw,et al.  [Detection, evaluation, and treatment of high blood cholesterol in adults]. , 2001, Revista panamericana de salud publica = Pan American journal of public health.

[63]  S. Ishibashi,et al.  Lipoprotein(a) and atherosclerosis. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[64]  F R Rosendaal,et al.  Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased , 1998 .

[65]  T. Matsuo,et al.  [Activated protein C resistance]. , 1998, Ryoikibetsu shokogun shirizu.

[66]  M. Pinotti,et al.  Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[67]  R. Press,et al.  Ischemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. , 1996, Stroke.

[68]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.